Charles Schwab Investment Management Inc. Purchases 40,813 Shares of Encompass Health Corporation (NYSE:EHC)

Charles Schwab Investment Management Inc. boosted its position in Encompass Health Corporation (NYSE:EHC) by 6.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 685,577 shares of the company’s stock after purchasing an additional 40,813 shares during the period. Charles Schwab Investment Management Inc. owned about 0.68% of Encompass Health worth $69,435,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Blair William & Co. IL boosted its holdings in Encompass Health by 0.8% during the 1st quarter. Blair William & Co. IL now owns 213,652 shares of the company’s stock valued at $21,639,000 after acquiring an additional 1,634 shares during the period. PNC Financial Services Group Inc. grew its holdings in Encompass Health by 2.3% in the first quarter. PNC Financial Services Group Inc. now owns 38,278 shares of the company’s stock valued at $3,877,000 after purchasing an additional 875 shares during the period. SPC Financial Inc. lifted its position in shares of Encompass Health by 0.9% in the first quarter. SPC Financial Inc. now owns 45,465 shares of the company’s stock valued at $4,605,000 after acquiring an additional 388 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Encompass Health during the first quarter worth approximately $274,000. Finally, Alberta Investment Management Corp acquired a new stake in Encompass Health during the first quarter worth $3,556,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Up 0.4%

NYSE:EHC opened at $119.62 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. The firm’s fifty day moving average is $116.16 and its 200-day moving average is $109.30. Encompass Health Corporation has a 52 week low of $87.36 and a 52 week high of $123.13. The firm has a market cap of $12.05 billion, a P/E ratio of 23.41, a P/E/G ratio of 2.08 and a beta of 0.86.

Encompass Health (NYSE:EHC) last issued its earnings results on Monday, August 4th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.20. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business earned $1.11 earnings per share. Equities analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be issued a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, October 1st. This represents a $0.76 annualized dividend and a yield of 0.6%. This is a positive change from Encompass Health’s previous quarterly dividend of $0.17. Encompass Health’s payout ratio is currently 13.31%.

Analyst Ratings Changes

Several research firms have recently weighed in on EHC. Barclays boosted their target price on Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Royal Bank Of Canada raised their price objective on Encompass Health from $110.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, April 28th. Truist Financial set a $140.00 price target on Encompass Health and gave the stock a “buy” rating in a research note on Thursday. KeyCorp lifted their price target on Encompass Health from $122.00 to $135.00 and gave the company an “overweight” rating in a report on Tuesday, May 27th. Finally, UBS Group upped their price target on Encompass Health from $130.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $134.00.

Insider Transactions at Encompass Health

In other news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer directly owned 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.00% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.